معرفی
Charles P. Scott is an Associate Professor in the Department of Biochemistry & Molecular Biology at Thomas Jefferson University's College of Life Sciences and Director of the Biomedical Sciences MS Program. His laboratory at the Bluemle Life Science Building focuses on discovering novel treatments for acute and chronic diseases through innovative drug development approaches.
His research encompasses three primary projects: (1) developing the PARIT chemical genomic platform for rapid druggable target identification through genetic cell instruction and selection; (2) creating new tuberculosis therapeutics by targeting mycobacterial respiration via type II NADH dehydrogenase (NDH-2) mechanism elucidation; and (3) designing next-generation asthma/COPD treatments using biased β2-adrenergic receptor agonists and desensitization pathway inhibitors to overcome tolerance issues with current beta-agonists. His work integrates high-throughput screening, virtual screening, and expression-based chemical genetics.
His 2024 Respiratory Research publication on G12/13 signaling in asthma demonstrates his focus on translating mechanistic insights into respiratory disease therapeutics, particularly through G protein-coupled receptor signaling pathways relevant to airway constriction.
Dr. Scott leads an active research team employing multi-pronged discovery methodologies to address global health challenges in infectious and chronic respiratory diseases, with his tuberculosis research directly influencing clinical trial initiatives through the Global Alliance for Tuberculosis Drug Development.
